Share on StockTwits
 

AstraZeneca (LON:AZN)‘s stock had its “market perform” rating reaffirmed by Sanford C. Bernstein in a research note issued on Tuesday, AR Network reports. They currently have a GBX 3,112 ($51.08) price target on the stock. Sanford C. Bernstein’s price target suggests a potential downside of 20.61% from the company’s current price.

AstraZeneca (LON:AZN) opened at 3935.2119 on Tuesday. AstraZeneca has a one year low of GBX 2895.00 and a one year high of GBX 3912.00. The stock has a 50-day moving average of GBX 3595.35 and a 200-day moving average of GBX 3335.60. The company’s market cap is £49.308 billion.

Other equities research analysts have also recently issued reports about the stock. Analysts at Swedbank reiterated a “reduce” rating on shares of AstraZeneca in a research note to investors on Monday. They now have a GBX 3,378.87 ($55.46) price target on the stock. Separately, analysts at Barclays reiterated an “equal weight” rating on shares of AstraZeneca in a research note to investors on Friday. They now have a GBX 3,300 ($54.17) price target on the stock. Finally, analysts at Panmure Gordon raised their price target on shares of AstraZeneca from GBX 3,200 ($52.53) to GBX 3,500 ($57.45) in a research note to investors on Thursday, January 16th. They now have a “sell” rating on the stock. Twelve investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of GBX 3,358.57 ($55.13).

AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.